All In Biotech

Drug Trial Radar · NCT07748403

A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)

A Phase 1/2 Clinical Study to Evaluate Safety, Tolerability, Biological Activity, and Initial Efficacy of Prime Editing (PM577a) for the Treatment of Wilson Disease (WD) in Adult and Adolescent Participants With at Least One Allele Harboring the p.H1069Q Mutation in ATP7B

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Nov 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Prime Medicine, Inc.Industry
Sponsor type
Industry
First posted
Aug 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, biological activity, and initial efficacy of PM577a, an investigational Prime Editing therapy, in adults and adolescents with Wilson disease (WD). Wilson disease is caused by changes (mutations) in the ATP7B gene that prevent the body from removing excess copper normally. PM577a is designed to precisely correct one of the most common disease-causing ATP7B mutations (p.H1069Q) in liver cells with the goal of restoring normal copper metabolism. This is the first study of PM577a in people. Participants will receive a single intravenous (IV) infusion of PM577a and will be monitored closely to evaluate safety, how the body responds to treatment, whether copper metabolism improves, and whether treatment may improve signs and symptoms of Wilson disease.

Conditions

  • Wilson Disease
  • Wilson's Disease
  • Wilsons Disease

Interventions

  • PM577aDrug

    PM577a is being evaluated in participants with Wilson disease caused by biallelic pathogenic, likely pathogenic, or suspected pathogenic ATP7B variants, including at least one p.H1069Q allele.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of PM577a. Quantified by frequency and severity of treatment emergent adverse events (TEAEs).Time frame: Post-infusion through Week 48

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Yale New Haven Hospital

    New Haven, Connecticut · Not yet recruiting

  • Northwestern University Division of Gastroenterology and Hepatology

    Chicago, Illinois · Not yet recruiting

  • ARC Texas Liver Institute

    San Antonio, Texas · Recruiting

  • New Zealand Clinical Research (NZCR)

    Grafton, Auckland, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.